Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Pi Industries Ltd. is currently prosecuting a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio contains 1 pending office action, which is assigned to MELLER, MICHAEL V. As the busiest examiner for the company, MELLER, MICHAEL V is managing 1 pending action, which accounts for the entire active workload. This prosecution is centralized within 1 distinct examiner and 1 distinct art unit, reflecting a focused technical scope.
The 1 pending office action in Biotechnology & Pharmaceuticals indicates a specific point of engagement with the USPTO. Since there is 1 distinct art unit involved, the company's current application is being reviewed within a single specialized group. The busiest examiner, MELLER, MICHAEL V, holds 1 pending action, matching the total number of pending office actions for the portfolio. This alignment means the company's current outcomes in this technology area are tied to the 1 distinct examiner currently assigned.
Practitioners should note that the 1 distinct examiner and 1 distinct art unit provide a singular channel for the company's current intellectual property efforts. With 1 pending office action, there is no current distribution of work across different examiners or units. This concentration under MELLER, MICHAEL V underscores the importance of this examiner's specific review process for the 1 pending office action currently in the pipeline.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 1 | 53.7% | +52.6% |
| MELLER, MICHAEL V | 1 | 47.2% | +28.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572818 | A COMBINATION OF FLUBENDIAMIDE AND SEAWEED EXTRACT | MELLER, MICHAEL V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720255 | SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | RICCI, CRAIG D | — |
| 18572818 | A COMBINATION OF FLUBENDIAMIDE AND SEAWEED EXTRACT | MELLER, MICHAEL V | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18720255 | SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | RICCI, CRAIG D | 1611 | §102 | Final Rejection | — | Pending | Jun 14, 2024 |
| 18572818 | A COMBINATION OF FLUBENDIAMIDE AND SEAWEED EXTRACT | MELLER, MICHAEL V | 1655 | §101§102§103 | Non-Final OA | — | Pending | Dec 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPi Industries Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Craig D Ricci has the most, with 1 of Pi Industries Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.